Feline infectious peritonitis (FIP) remains one of the most studied — and most commercially active — small-animal antiviral research fields. As GS-441524 monotherapy becomes standard, a growing body of literature and buyer demand now centers on combination strategies, especially for drug-resistant or refractory FIP-V strains. The most discussed pairing is GS-441524 (RdRp) + GC376 (3CL-Pro): two unrelated viral targets, one synergistic goal. This guide explains the rationale and maps the full catalog of lab-grade FIPV research compounds by mechanism.
1. Why Combine GS-441524 with GC376?
Feline coronavirus (FCoV) replication depends on two enzyme families that are chemically and genetically independent:
- RNA-dependent RNA polymerase (RdRp) — replicates the viral genome. Inhibited by nucleoside analogs such as GS-441524.
- 3C-like protease (3CL-Pro / Mpro) — cleaves the viral polyprotein into functional non-structural proteins. Inhibited by covalent warhead compounds such as GC376.
Because resistance to one class rarely confers cross-resistance to the other, a dual-mechanism regimen raises the genetic barrier to treatment failure. In refractory or suspected-resistant cases, researchers combine a nucleoside backbone with a protease inhibitor to suppress breakthrough replication and to probe compensatory mutations in the FIPV genome.
2. Two-Pronged Mechanism at a Glance
Target A — Viral RdRp (nucleoside class)
GS-441524 and its relatives are incorporated into the nascent viral RNA chain, causing premature termination or (in the case of mutagenic analogs) error catastrophe. This class is the global front-runner for FIP-V work.
Target B — Viral 3CL-Pro (protease class)
GC376 and analogs carry an aldehyde / electrophilic warhead that covalently traps the protease active-site cysteine, blocking polyprotein processing. This is the industry benchmark protease reagent for both wet and dry FIP models.
3. The FIP-V Research Compound Catalog
Below is a structured catalog of lab-grade anti-FIPV raw materials, grouped into the five mechanism/use classes researchers most frequently source. Each entry lists CAS, target / mechanism, applicable research direction, and a short FIP market note.
3CL-Pro Protease Inhibitors
The protease-inhibitor arm of the combination. Covalent warhead compounds that block FIPV polyprotein cleavage — the benchmark class for wet and dry FIP studies and the natural partner to GS-441524.
| Compound | CAS | Target / Mechanism | Applicable Research Direction | FIP Market Note |
|---|---|---|---|---|
| GC-376 | — | FIPV-3CL-Pro covalent inhibitor (aldehyde warhead) | Wet-type & dry-type FIP mainstream research; protease-arm of GS-441524 combos | Industry benchmark mainstay FIP reagent |
| GC-376 Sodium | — | Water-soluble sodium salt of GC-376 (same 3CL-Pro covalent target) | Aqueous / water-soluble formulation studies | High-frequency overseas search; better water solubility than parent |
| GC-373 | 2305708-50-8 | Aldehyde-warhead 3CL-Pro inhibitor; GC376 precursor | Broad-spectrum coronavirus protease inhibition | Precursor / broad-spectrum tool |
| Nirmatrelvir (PF-07321332) | 2628280-40-4 | Peptide-class reversible 3CL-Pro inhibitor | FIPV in-vitro control experiments (extensively cited) | Widely used control |
| Ensitrelvir (S-217622) | 2640036-24-4 | Non-peptide broad-spectrum coronavirus Mpro inhibitor | Resistant-strain FIP studies | Common for resistant strains |
RdRp Nucleoside Inhibitors
The polymerase-inhibitor arm — the globally hottest FIP-V research class. Nucleoside analogs terminate or mutate viral RNA; the GS-441524 family is the first-line backbone in dry, neuro and ocular FIP models.
| Compound | CAS | Target / Mechanism | Applicable Research Direction | FIP Market Note |
|---|---|---|---|---|
| GS-441524 | 1191237-69-0 | Viral RNA-dependent RNA polymerase (RdRp) | Dry-type, neuro-type & ocular FIP first-choice reagent | Globally hottest FIP-V material |
| GS-441524 Hydrochloride | 2378280-82-9 | Water-soluble HCl salt of GS-441524 (RdRp) | Aqueous formulations, injectable suspension studies | Huge overseas procurement volume |
| Remdesivir (GS-5734) | 1809249-37-3 | GS-441524 parent prodrug; broad-spectrum coronavirus RdRp inhibitor | Broad-spectrum coronavirus research | Reference prodrug |
| Molnupiravir | 2349386-89-4 | Nucleoside mutagen (RdRp error catastrophe) | Resistant-strain & combination-therapy topics | Hot combination-therapy material |
Second-Generation Derivatives
Optimized successors of the benchmark protease inhibitors — designed for higher selectivity and lower off-target toxicity, and an emerging overseas research favorite.
| Compound | CAS | Target / Mechanism | Applicable Research Direction | FIP Market Note |
|---|---|---|---|---|
| NK01-63 (Coronastat) | 2922281-15-8 | Optimized 2nd-gen GC376 derivative; 3CL-Pro inhibitor | Higher selectivity, lower off-target toxicity vs GC376 | Emerging hot overseas material |
Backup / Control Reagents
Host-targeting and cyclophilin inhibitors used as classic control groups and as backup options when nucleoside / protease monotherapy stalls — essential for rigorous resistance studies.
| Compound | CAS | Target / Mechanism | Applicable Research Direction | FIP Market Note |
|---|---|---|---|---|
| Cyclosporin A | 59865-13-3 | Cyclophilin inhibitor; blocks FIPV host-protein interaction | Classic control-group reagent | Standard control |
| F83233 | — | Potent cyclophilin inhibitor (stronger than Cyclosporin A) | Front-edge FIP research, high-frequency material | Emerging front-edge material |
Synergistic Adjuvant Compounds
Novel host-targeting agents that complement the GS-441524 + GC376 core — blocking viral entry or replication through independent pathways, frequently tested in resistance-direction combination screens.
| Compound | CAS | Target / Mechanism | Applicable Research Direction | FIP Market Note |
|---|---|---|---|---|
| Imipramine | 50-49-7 | NPC1 cholesterol-pathway inhibitor; blocks FIPV host-cell entry | Novel host-target inhibitor studies | Novel host-target candidate |
| Mefloquine | 53230-10-7 | Inhibits feline coronavirus replication | GS-441524 resistance-direction testing | Used in resistance testing |
4. Designing a Resistant-Strain Combination Study
A typical in-vitro or animal-model resistance study pairs the two cores and layers controls and adjuvants:
- Backbone: GS-441524 (or GS-441524 HCl for aqueous work) at graded concentrations.
- Protease arm: GC-376 / GC-376 Sodium added at a fixed or titrated ratio.
- Controls: Cyclosporin A or F83233 as host-target negative/orthogonal controls; Nirmatrelvir / Ensitrelvir as independent 3CL-Pro comparators.
- Adjuvants: Imipramine or Mefloquine screened for entry/replication synergy in refractory strains.
- Next-gen: NK01-63 substituted for GC376 to assess selectivity / toxicity trade-offs.
5. Sourcing & QC Considerations
When procuring lab-grade anti-FIPV raw materials, prioritize:
- Verified identity & purity — HPLC ≥98% with COA, NMR/HMBC structural confirmation.
- Form flexibility — water-soluble salts (GC-376 Sodium, GS-441524 HCl) for aqueous assays.
- Batch traceability — MSDS/SDS and Certificate of Origin for audit-ready research.
- Breadth of catalog — sourcing 3CL-Pro, RdRp, 2nd-gen, control and adjuvant classes from one supplier simplifies combination studies.
Conclusion
The GS-441524 + GC376 combination represents the most actively researched dual-mechanism strategy against drug-resistant FIP-V, pairing an RdRp nucleoside backbone with a 3CL-Pro protease inhibitor to raise the resistance barrier. Whether you are building a combination screen, a resistant-strain model, or simply need orthogonal controls, the five-class catalog above covers the compounds driving today's feline coronavirus research.